Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03525873
Other study ID # 2017-0913
Secondary ID NCI-2018-0069820
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date August 2, 2018
Est. completion date December 31, 2024

Study information

Verified date April 2024
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase III trial studies how well methylphenidate and physical activity works in reducing cancer-related fatigue in patients who are receiving anti-PD1 immunotherapy for cancer that has spread to other places in the body. Central nervous systems stimulants, such as methylphenidate, may help to improve cognitive function. Physical activity uses techniques, such as aerobic and resistance exercises, which may help to improve quality of life. Giving methylphenidate and physical activity may help in reducing cancer-related fatigue in patients with metastatic cancer who receive anti-PD1 immunotherapy.


Description:

PRIMARY OBJECTIVES: I. To determine the effects of methylphenidate plus physical activity (MP) compared to placebo plus physical activity (PL) in reducing cancer-related fatigue (CRF) in patients with metastatic cancer on anti-PD1 immunotherapy, as measured by changes in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale scores after 2 weeks of intervention. SECONDARY OBJECTIVES: I. To explore the effect of MP on anxiety (Hospital Anxiety and Depression Scale [HADS]), depressed mood (HADS), cancer symptoms (Edmonton Symptom Assessment Scale (ESAS), physical activity (mean day time activity as measured by actigraphy), and serum levels of inflammatory cytokines (IL-1beta, IL-1 RA, IL-6, TNF-alpha, IL-8, IL-10, and MCP1), before and after treatment. EXPLORATORY OBJECTIVES: I. To determine the frequency and factors associated with CRF as assessed by FACIT-F, Patient-Reported Outcomes Measurement Information System Fatigue (PROMIS-F), Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), actigraphy, Edmonton Symptom Assessment System (ESAS), and serum levels of inflammatory cytokines (IL-1beta, IL-1 RA, IL-6, TNF-alpha, IL-10, IL-8, MCP-1), before and during 4 initial doses of Immunotherapy. II. To explore the effects of MP on percentage (%) of patients with dose reduction and/or discontinuation anti-PD1 immunotherapy due to CRF. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive methylphenidate orally (PO) twice daily (BID) for up to 2 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete physical activity consisting of walking and resistance exercise over 25-40 minutes once daily (QD) 4 days a week. After 2 weeks, patients may continue methylphenidate at the discretion of the treating physician for up to 12 weeks in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive a matched placebo PO BID and complete physical activity as in Arm I.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 212
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Part 1: have a diagnosis of metastatic or recurrent cancer and previously received anti PD1 immunotherapy provided that they received therapy up to 1 month prior to enrollment - Part 1: be willing to engage in follow-up telephone calls with a research staff - Part 1: have telephone access so they can be contacted by the research staff - Part 1: hemoglobin level of >= 8 g/dL within 2 weeks of enrollment * Packed red blood cell (PRBC) transfusions will be allowed to patients with hemoglobin < 8 g/dl - Part 1: be able to understand the description of the study and give written informed consent - Part 1: able to read, write and speak English - Part 2: have a diagnosis of metastatic or recurrent cancer and previously received anti PD1 immunotherapy provided that they received therapy up to 1 month prior to enrollment - Part 2: be willing to engage in follow-up telephone calls with a research staff - Part 2: have telephone access so they can be contacted by the research staff - Part 2: have a hemoglobin level of >=8 g/dL within 2 weeks of enrollment * PRBC transfusions will be allowed to patients with hemoglobin < 8 g/dl - Part 2: be able to understand the description of the study and give written or verbal informed consent - Part 2: able to read, write and speak English - Part 2: presence of fatigue as defined FACIT-F subscale of =< 34 on a 0 to 52 scale (in which 52 = no fatigue and 0 = worst possible fatigue) - Part 2: not currently taking methylphenidate, or have taken it within the previous 10 days - Part 2: able to complete the baseline assessment forms - Part 2: able to understand the recommendations for participation in the study - Part 2: can be enrolled directly to part 2 independent of part 1 if on immunotherapy and having a FACIT-F fatigue =< 34, and able to complete baseline assessment and bloodwork as detailed in Part 1 at baseline and day 14 +/-3 days. Treating Oncologist should agree for participation in the intervention trial Exclusion Criteria: - Part 1: patients will be excluded if (1) have clinical evidence of cognitive failure as evidenced by Memorial Delirium Assessment Scale score of >= 13 at baseline completed in person, by phone, or via video-conference - Part 2: Patients will be excluded if (1) have clinical evidence of cognitive failure as evidenced by Memorial Delirium Assessment Scale score of >= 13 at baseline completed in person, by phone, or via video-conference - Part 2: have a major contraindication to MP (e.g., allergy/hypersensitivity to study medications or their constituents), or conditions making adherence difficult as determined by the attending physician - Part 2: on monoamine oxidase inhibitors, tricyclic antidepressants, or clonidine - Part 2: history of glaucoma - Part 2: history of have severe cardiac disease (New York Heart Association functional class III or IV) - Part 2: tachycardia and/or uncontrolled hypertension - Part 2: currently receiving anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and/or tricyclic drugs (imipramine, clomipramine, or desipramine) - Part 2: patients with Cut Down, Annoyed, Guilty and Eye Opener-Adapted to Include Drugs (CAGE-AID) >= 2

Study Design


Intervention

Other:
Laboratory Biomarker Analysis
Correlative studies
Drug:
Methylphenidate
Given PO
Other:
Physical Activity
Participate in physical activity
Placebo
Given PO
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Assessment of MP effects on levels of serum IL-1b, IL-1 RA, IL-6, TNF-a, IL-8,IL-10, and MCP1 To be assessed using blood samples obtained from participants. To be evaluated using descriptive statistical analyses. A t test will be used to evaluate the difference between groups unless the data appear to be non-normally distributed, in which case a Wilcoxon rank-sum test will be used to evaluate the difference between groups. Will summarize percentage (%) of patients with stable CRF scores, % patients who had dose change and/ or discontinuation of anti-PD1 immunotherapy due to CRF. At weeks 2, 6, and 10
Primary Assessment of the effects of methylphenidate (MP) plus physical activity in reducing cancer-related fatigue (CRF) Effects of MP to be compared to placebo plus physical activity results. To be as measured by changes in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) sub-scale scores. A t test will be used to evaluate the difference between groups unless the data appear to be non-normally distributed, in which case a Wilcoxon rank-sum test will be used to evaluate the difference between groups. Up to 12 weeks
Secondary Assessment of MP effects on physical activity To be measured by mean day time activity (actigraphy). To be evaluated using descriptive statistical analyses. A t test will be used to evaluate the difference between groups unless the data appear to be non-normally distributed, in which case a Wilcoxon rank-sum test will be used to evaluate the difference between groups. Will summarize percentage (%) of patients with stable CRF scores, % patients who had dose change and/ or discontinuation of anti-PD1 immunotherapy due to CRF. Up to 12 weeks
Secondary Assessment of MP effects on anxiety, depressed mood, and cancer symptoms by questionnaires To be assessed using statistical methods described in primary outcomes and using outcome variables including Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for fatigue dimensions Up to 5 minutes during visit
Secondary Assessment of MP effects on anxiety, depressed mood, and cancer symptoms by questionnaires To be assessed using statistical methods described in primary outcomes and using outcome variables including Patient-Reported Outcomes Measurement Information System Fatigue (PROMIS) for fatigue dimensions Up to 5 minutes during visit
Secondary Assessment of MP effects on anxiety, depressed mood, and cancer symptoms by questionnaires To be assessed using statistical methods described in primary outcomes and using outcome variables including Hospital Anxiety and Depression Scale (HADS) for anxiety/depression Up to 5 minutes during visit
Secondary Assessment of MP effects on anxiety, depressed mood, and cancer symptoms by questionnaires To be assessed using statistical methods described in primary outcomes and using outcome variables including Functional Assessment of Cancer Therapy-General (FACT-G) for Quality of Life. Up to 5 minutes during visit
Secondary Assessment of MP effects on anxiety, depressed mood, and cancer symptoms by questionnaires To be assessed using statistical methods described in primary outcomes and using outcome variables including Edmonton Symptom Assessment System (ESAS), (0-10 scale for sleep disturbance, fatigue, and drowsiness). Up to 5 minutes during visit
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03671226 - Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center N/A
Recruiting NCT05048160 - A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm Phase 1/Phase 2
Active, not recruiting NCT03287492 - RCT of QPS vs General Information Sheet N/A
Recruiting NCT01549067 - The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey N/A
Recruiting NCT04119037 - Cordotomy in Reducing Pain in Patients With Advanced Cancer N/A
Recruiting NCT04067336 - First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT04585750 - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Phase 1/Phase 2
Completed NCT02823652 - Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer N/A
Completed NCT00244972 - Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer Phase 1
Active, not recruiting NCT01582191 - Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer Phase 1
Active, not recruiting NCT03856060 - Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits N/A
Completed NCT04186884 - Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
Completed NCT02583269 - Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery Phase 1
Withdrawn NCT03868423 - Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Phase 2
Terminated NCT02940223 - Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer Phase 2
Active, not recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Active, not recruiting NCT03021486 - Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer Phase 2/Phase 3
Recruiting NCT03203525 - Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer Phase 1
Completed NCT01624766 - Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers Phase 1
Not yet recruiting NCT06394713 - A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors Phase 1/Phase 2